Outcome of 87 patients with NK/T-cell lymphoma treated with SMILE
| Treatment and outcome . | Nasal . | Nonnasal . | Disseminated . | Overall . |
|---|---|---|---|---|
| Newly diagnosed patients | ||||
| No. of patients | 29 | 11 | 3 | 43 |
| Median total courses of SMILE (range) | 4 (0-6) | 3 (2-6) | 2 (1-3) | 4 (0-6) |
| Regimen-related toxic death | 2 (7) | 1 (9) | 0 | 3 (7) |
| Outcome on interim analysis* | ||||
| CR | 20 (69) | 4 (36) | 2 (67) | 26 (60) |
| PR | 5 (17) | 3 (27) | 1 (33) | 9 (21) |
| Nonremission | 2 (7) | 3 (27) | 0 | 5 (11) |
| Outcome on completion of treatment† | ||||
| CR | 20 (69) | 6 (55) | 2 (67) | 28 (65) |
| PR | 6 (21) | 2 (18) | 0 | 8 (19) |
| Nonremission | 1 (3) | 2 (18) | 1 (33) | 4 (9) |
| Clinical course of patients with complete remission | ||||
| Continued remission | 15 | 1 | 0 | 16 |
| Continued remission after HSCT | 2 | 2 | 1 | 5 |
| Relapse after SMILE or HSCT | 2 | 3 | 1 | 6 |
| Death due to unrelated causes while still in remission‡ | 1 | 0 | 0 | 1 |
| Outcome of patients with PR or nonremission | ||||
| Remission after salvage treatment | 1 | 0 | 0 | 1 |
| Surviving with disease | 1 | 2 | 0 | 3 |
| Death due to progressive disease | 5 | 2 | 1 | 8 |
| Relapsed/refractory patients | ||||
| No. of patients | 31 | 10 | 3 | 44 |
| Median total courses of SMILE (range) | 3 (1-6) | 3 (1-6) | 4 (3-6) | 3 (1-6) |
| Regimen-related toxic death (%) | 2 (6) | 1 (10) | 0 | 3 (7) |
| Outcome on interim analysis* | ||||
| CR (%) | 14 (45) | 7 (70) | 2 (67) | 23 (52) |
| PR (%) | 8 (26) | 1 (10) | 1 (33) | 10 (23) |
| Nonremission (%) | 6 (19) | 1 (10) | 0 | 7 (16) |
| Not performed (%) | 1 (3) | 0 | 0 | 1 (2) |
| Outcome on completion of treatment† | ||||
| CR (%) | 20 (65) | 7 (70) | 2 (67) | 29 (66) |
| PR (%) | 3 (10) | 1 (10) | 1 (33) | 5 (11) |
| Nonremission (%) | 6 (19) | 1 (10) | 0 | 7 (16) |
| Clinical course of patients with CR | ||||
| Continued remission | 10 | 1 | 1 | 12 |
| Continued remission after HSCT | 6 | 1 | 1 | 8 |
| Relapse after SMILE or HSCT | 3 | 4 | 0 | 7 |
| Death due to subsequent therapy§ | 1 | 0 | 0 | 1 |
| Death due to unrelated causes‖ | 0 | 1 | 0 | 1 |
| Outcome of patients with PR or nonremission | ||||
| Remission after salvage treatment | 1 | 0 | 0 | 1 |
| Surviving with disease | 0 | 1 | 0 | 1 |
| Lost to follow-up | 1 | 0 | 0 | 1 |
| Death due to progressive disease | 7 | 1 | 1 | 9 |
| Treatment and outcome . | Nasal . | Nonnasal . | Disseminated . | Overall . |
|---|---|---|---|---|
| Newly diagnosed patients | ||||
| No. of patients | 29 | 11 | 3 | 43 |
| Median total courses of SMILE (range) | 4 (0-6) | 3 (2-6) | 2 (1-3) | 4 (0-6) |
| Regimen-related toxic death | 2 (7) | 1 (9) | 0 | 3 (7) |
| Outcome on interim analysis* | ||||
| CR | 20 (69) | 4 (36) | 2 (67) | 26 (60) |
| PR | 5 (17) | 3 (27) | 1 (33) | 9 (21) |
| Nonremission | 2 (7) | 3 (27) | 0 | 5 (11) |
| Outcome on completion of treatment† | ||||
| CR | 20 (69) | 6 (55) | 2 (67) | 28 (65) |
| PR | 6 (21) | 2 (18) | 0 | 8 (19) |
| Nonremission | 1 (3) | 2 (18) | 1 (33) | 4 (9) |
| Clinical course of patients with complete remission | ||||
| Continued remission | 15 | 1 | 0 | 16 |
| Continued remission after HSCT | 2 | 2 | 1 | 5 |
| Relapse after SMILE or HSCT | 2 | 3 | 1 | 6 |
| Death due to unrelated causes while still in remission‡ | 1 | 0 | 0 | 1 |
| Outcome of patients with PR or nonremission | ||||
| Remission after salvage treatment | 1 | 0 | 0 | 1 |
| Surviving with disease | 1 | 2 | 0 | 3 |
| Death due to progressive disease | 5 | 2 | 1 | 8 |
| Relapsed/refractory patients | ||||
| No. of patients | 31 | 10 | 3 | 44 |
| Median total courses of SMILE (range) | 3 (1-6) | 3 (1-6) | 4 (3-6) | 3 (1-6) |
| Regimen-related toxic death (%) | 2 (6) | 1 (10) | 0 | 3 (7) |
| Outcome on interim analysis* | ||||
| CR (%) | 14 (45) | 7 (70) | 2 (67) | 23 (52) |
| PR (%) | 8 (26) | 1 (10) | 1 (33) | 10 (23) |
| Nonremission (%) | 6 (19) | 1 (10) | 0 | 7 (16) |
| Not performed (%) | 1 (3) | 0 | 0 | 1 (2) |
| Outcome on completion of treatment† | ||||
| CR (%) | 20 (65) | 7 (70) | 2 (67) | 29 (66) |
| PR (%) | 3 (10) | 1 (10) | 1 (33) | 5 (11) |
| Nonremission (%) | 6 (19) | 1 (10) | 0 | 7 (16) |
| Clinical course of patients with CR | ||||
| Continued remission | 10 | 1 | 1 | 12 |
| Continued remission after HSCT | 6 | 1 | 1 | 8 |
| Relapse after SMILE or HSCT | 3 | 4 | 0 | 7 |
| Death due to subsequent therapy§ | 1 | 0 | 0 | 1 |
| Death due to unrelated causes‖ | 0 | 1 | 0 | 1 |
| Outcome of patients with PR or nonremission | ||||
| Remission after salvage treatment | 1 | 0 | 0 | 1 |
| Surviving with disease | 0 | 1 | 0 | 1 |
| Lost to follow-up | 1 | 0 | 0 | 1 |
| Death due to progressive disease | 7 | 1 | 1 | 9 |